Status:

RECRUITING

Alzheimer's National Registry for Treatment and Diagnostics(ALZ-NET)

Lead Sponsor:

Alzheimer's Disease and Related Disorders Association, Inc

Collaborating Sponsors:

American College of Radiology

The Critical Path Institute

Conditions:

Alzheimer Disease

Eligibility:

All Genders

18+ years

Brief Summary

The Alzheimer's Network for Treatment and Diagnostics (ALZ-NET) will collect longitudinal clinical and safety data for enrolled patients being evaluated for or treated with novel FDA-approved Alzheime...

Detailed Description

ALZ-NET is collecting longitudinal clinical and safety data for enrolled patients that are being evaluated for or being treated with novel FDA-approved AD therapies. ALZ-NET is a longitudinal registry...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Patient or patient's legally authorized representative (LAR) or proxy (e.g., spouse or legal guardian) has the ability to understand the purpose and risks of ALZ-NET and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local patient privacy regulations.
  • Patient is at least 18 years of age at the time of informed consent.
  • Patient has a diagnosis of MCI or dementia with clinical suspicion of AD as contributing pathology and (1) is being evaluated for treatment or, (2) will be initiating treatment, or (3) has already initiated treatment with novel FDA-approved AD therapies in real-world clinical practice.
  • If treatment is initiated at the time of consent, patient meets appropriate label requirements and treatment follows appropriate use recommendations for novel FDA-approved AD therapy/therapies.
  • Patient's treating clinician has made the decision to provide clinical care or treatment prior to patient consent and independently of the purpose of ALZ-NET.

Exclusion

    Key Trial Info

    Start Date :

    October 20 2022

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ESTIMATED

    End Date :

    December 1 2032

    Estimated Enrollment :

    20000 Patients enrolled

    Trial Details

    Trial ID

    NCT06170268

    Start Date

    October 20 2022

    End Date

    December 1 2032

    Last Update

    December 14 2023

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Full List of Active Sites

    Chicago, Illinois, United States, 60601